Electrostimulation (ES) can be defined as a safe physical method to induce stem cell differentiation. The aim of this study is to evaluate the effectiveness of ES on bone marrow mesenchymal stem cells (BMSCs) seeded in collagen scaffolds in terms of proliferation and differentiation into cardiomyocytes. BMSCs were isolated from Wistar rats and seeded into 3D collagen type 1 templates measuring 25 x 25 x 6 mm. Bipolar in vitro ES was performed during 21 days. Electrical impedance and cell proliferation were measured. Expression of cardiac markers was assessed by immunocytochemistry. Viscoelasticity of collagen matrix was evaluated. Electrical impedance assessments showed a low resistance of 234±41 Ohms which indicates good electrical conductivity of collagen matrix. Cell proliferation at 570 nm as significantly increased in ES groups after seven day (ES 0.129±0.03 vs non-stimulated control matrix 0.06±0.01, P=0.002) and after 21 days, (ES 0.22±0.04 vs control 0.13±0.01, P=0.01). Immunocytoche mistry of BMSCs after 21 days ES showed positive staining of cardiac markers, troponin I, connexin 43, sarcomeric alpha-actinin, slow myosin, fast myosin and desmin. Staining for BMSCs marker CD29 after 21 days was negative. Electrostimulation of cell-seeded collagen matrix changed stem cell morphology and biochemical characteristics, increasing the expression of cardiac markers. Thus, MSCderived differentiated cells by electrostimulation grafted in biological scaffolds might result in a convenient tissue engineering source for myocardial diseases.
Electrostimulation, collagen scaffold, stem cells, cell conditioning, myocardial infarct, heart failure, bioartificial myocardium
Juan Carlos Chachques, Georges Pompidou Hospital, Laboratory of Biosurgical Research, 56 rue Leblanc, 75015 Paris, France. Tel: +33.613144398, Fax: +33.156095903 E-mail: email@example.com
The authors would thank
Yves Lecarpentier and Jean-Louis Hebert
(Bicetre Hospital, Paris, France), Jean-Baptiste
Michel (Inserm, Bichat Hospital, Paris, France)
and Pierre Grandjean (Carpentier Foundation,
Paris, France) for their scientific collaboration.
Share this Article
Related Content In Heart Failure
49/Multi-disciplinary heart failure- Device clinic improves management of heart failure patients following complex device implantatio
European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr49
Introduction: Complex device therapy (CDT) [cardiac resynchronisation therapy pacemaker or defibrillator (CRTP or CRTD) and implantable cardioverter defibrillator (ICD)], is recommended in patients with heart failure (HF) with severe left ventricular systolic dysfunction if they are still symptomatic despite optimisation HF medication. Several patients however, will only tolerate optimal doses of these drugs after CDT, […]
47/Association between very high NT-proBNP levels, and haemoglobin and ferritin
European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr47
Introduction: The adverse prognosis in heart failure (HF) correlates with both NT-proBNP and high-sensitivity CRP levels. The latter indicates a greater underlying inflammatory process in more severe heart failure. This inflammatory response is also evidenced by elevated ferritin (acute phase reactant) and reduced haemoglobin (bone marrow suppression) amongst these patients. It is unclear if there […]
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!